Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a three-day pill course after joint replacement speed up recovery?

NCT ID NCT07685743

Disease control Sponsor: Oregon Health and Science University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This trial tests whether taking the anti-bleeding medication tranexamic acid (TXA) for three days after hip or knee replacement surgery helps people recover faster and with less pain. Adults with osteoarthritis who are having a first-time joint replacement receive either TXA or a placebo pill on days 1, 2, and 3 after surgery, in addition to standard TXA given before the incision. Researchers measure joint function, pain, and range of motion at 2, 6, and 12 weeks after surgery to see if the extended TXA regimen improves outcomes without raising complication risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tranexamic acid (TXA)
What this could lead to
If it works, this could lead to a simple, low-cost way to improve recovery and reduce blood loss after joint replacement surgery.
What could go wrong
This is a small, early-phase trial, so results may not apply to all patients. TXA can rarely cause blood clots or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 170 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥18 years * Undergoing primary total knee arthroplasty (TKA) or total hip arthroplasty (THA) for osteoarthritis * Ability to provide written informed consent * Willingness to comply with study protocol Exclusion Criteria: * History of venous thromboembolism (DVT or PE) * Active malignancy * Allergy or contraindication to tranexamic acid (TXA) * Post-operative anticoagulation therapy other than aspirin * History of color blindness or retinal disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoarthritis (OA) of the hip are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoarthritis osteoarthritis, hip osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoarthritis (OA) of the hip Osteoarthritis (OA) of the knee

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.